Shots:

• The approval follows the REWIND study which involves assessing of Trulicity + SoC (1.5mg) vs PBO + SoC in adults with T2D
• The study showed reduction in MACE events and the profile of Trulicity was consistent with the GLP-1 receptor agonist (RA) class
• Trulicity is an injectable prescription medicine for adults with T2D used for the improving blood sugar level and reduction of MACE

Click here to read full press release/ article 

Ref: Eli Lilly | Image: Eli Lilly